Activity of decitabine in pericardial myeloid sarcoma

Int J Hematol. 2018 Aug;108(2):121-122. doi: 10.1007/s12185-018-2470-y. Epub 2018 May 19.

Authors

Dorothea Evers¹, Brigitte M A M Bär¹, Martin Gotthardt², Walter J F M van der Velden³

Affiliations

¹ Department of Hematology, Radboud University Medical Center, Geert Grooteplein 8, 6500 HB, Nijmegen, The Netherlands.
² Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
³ Department of Hematology, Radboud University Medical Center, Geert Grooteplein 8, 6500 HB, Nijmegen, The Netherlands. [email protected].

PMID: 29779081
DOI: 10.1007/s12185-018-2470-y

No abstract available

Keywords: Acute myeloid leukemia; Decitabine; Hypomethylating agent; Myeloid sarcoma; Pericardium.

Publication types

Case Reports
Letter

MeSH terms

Allografts
Antimetabolites, Antineoplastic / administration & dosage*
Azacitidine / administration & dosage
Azacitidine / analogs & derivatives*
Consolidation Chemotherapy
Decitabine
Drug Administration Schedule
Female
Heart Neoplasms / diagnosis
Heart Neoplasms / etiology
Heart Neoplasms / therapy*
Humans
Leukemia, Myeloid, Acute / complications
Pericardium*
Positron Emission Tomography Computed Tomography
Remission Induction
Sarcoma, Myeloid / diagnosis
Sarcoma, Myeloid / etiology
Sarcoma, Myeloid / therapy*
Stem Cell Transplantation / adverse effects
Stem Cell Transplantation / methods
Treatment Outcome

Substances

Antimetabolites, Antineoplastic
Decitabine
Azacitidine